194 related articles for article (PubMed ID: 35604523)
1. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.
Grégoire J; Champsi S; Jobin M; Martinez L; Urbich M; Rogoza RM
Adv Ther; 2022 Jul; 39(7):3262-3279. PubMed ID: 35604523
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
Xie W; Song Y; Qin X; Jin P
Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
[TBL] [Abstract][Full Text] [Related]
4. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.
Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
JAMA Cardiol; 2019 Jul; 4(7):691-695. PubMed ID: 31166576
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Inclisiran in Atherosclerotic Cardiovascular Patients with Elevated Low-Density Lipoprotein Cholesterol Despite Statin Use: A Threshold Analysis.
Desai NR; Campbell C; Electricwala B; Petrou M; Trueman D; Woodcock F; Cristino J
Am J Cardiovasc Drugs; 2022 Sep; 22(5):545-556. PubMed ID: 35595929
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
[TBL] [Abstract][Full Text] [Related]
9. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
10. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
[TBL] [Abstract][Full Text] [Related]
14. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels.
Svensson MK; James S; Ravn-Fischer A; Villa G; Schalin L; Cars T; Gustafsson S; Hagström E
Ups J Med Sci; 2024; 129():. PubMed ID: 38327639
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
[TBL] [Abstract][Full Text] [Related]
17. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
[TBL] [Abstract][Full Text] [Related]
18. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
Lehrke M; Vogt A; Schettler V; Girndt M; Fraass U; Tabbert-Zitzler A; Bridges I; Dhalwani NN; Ray KK
Adv Ther; 2024 Mar; 41(3):1184-1200. PubMed ID: 38286961
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
Bohula EA; Marston NA; Ruzza A; Murphy SA; De Ferrari GM; Diaz R; Leiter LA; Elliott-Davey M; Wang H; Bhatia AK; Giugliano RP; Sabatine MS
Am Heart J; 2024 Mar; 269():179-190. PubMed ID: 38160917
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]